These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 36866681)

  • 1. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
    Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants.
    Hwang HS; Nitu FR; Yang Y; Walweel K; Pereira L; Johnson CN; Faggioni M; Chazin WJ; Laver D; George AL; Cornea RL; Bers DM; Knollmann BC
    Circ Res; 2014 Mar; 114(7):1114-24. PubMed ID: 24563457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinctive malfunctions of calmodulin mutations associated with heart RyR2-mediated arrhythmic disease.
    Vassilakopoulou V; Calver BL; Thanassoulas A; Beck K; Hu H; Buntwal L; Smith A; Theodoridou M; Kashir J; Blayney L; Livaniou E; Nounesis G; Lai FA; Nomikos M
    Biochim Biophys Acta; 2015 Nov; 1850(11):2168-76. PubMed ID: 26164367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
    Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
    PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel CPVT-Associated Calmodulin Mutation in CALM3 (CALM3-A103V) Activates Arrhythmogenic Ca Waves and Sparks.
    Gomez-Hurtado N; Boczek NJ; Kryshtal DO; Johnson CN; Sun J; Nitu FR; Cornea RL; Chazin WJ; Calvert ML; Tester DJ; Ackerman MJ; Knollmann BC
    Circ Arrhythm Electrophysiol; 2016 Aug; 9(8):. PubMed ID: 27516456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
    Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
    Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
    Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL
    EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction.
    Xu X; Yano M; Uchinoumi H; Hino A; Suetomi T; Ono M; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ikemoto N; Matsuzaki M
    Biochem Biophys Res Commun; 2010 Apr; 394(3):660-6. PubMed ID: 20226167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arrhythmogenic Calmodulin Mutations Affect the Activation and Termination of Cardiac Ryanodine Receptor-mediated Ca2+ Release.
    Søndergaard MT; Tian X; Liu Y; Wang R; Chazin WJ; Chen SR; Overgaard MT
    J Biol Chem; 2015 Oct; 290(43):26151-62. PubMed ID: 26309258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation-linked, excessively tight interaction between the calmodulin binding domain and the C-terminal domain of the cardiac ryanodine receptor as a novel cause of catecholaminergic polymorphic ventricular tachycardia.
    Nishimura S; Yamamoto T; Nakamura Y; Kohno M; Hamada Y; Sufu Y; Fukui G; Nanno T; Ishiguchi H; Kato T; Xu X; Ono M; Oda T; Okuda S; Kobayashi S; Yano M
    Heart Rhythm; 2018 Jun; 15(6):905-914. PubMed ID: 29427818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arrhythmogenic calmodulin E105A mutation alters cardiac RyR2 regulation leading to cardiac dysfunction in zebrafish.
    Da'as SI; Thanassoulas A; Calver BL; Beck K; Salem R; Saleh A; Kontogianni I; Al-Maraghi A; Nasrallah GK; Safieh-Garabedian B; Toft E; Nounesis G; Lai FA; Nomikos M
    Ann N Y Acad Sci; 2019 Jul; 1448(1):19-29. PubMed ID: 30937913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
    J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
    Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
    Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
    Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B
    Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calmodulin Mutations in Human Disease.
    Hussey JW; Limpitikul WB; Dick IE
    Channels (Austin); 2023 Dec; 17(1):2165278. PubMed ID: 36629534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ryanodine receptor-bound calmodulin is essential to protect against catecholaminergic polymorphic ventricular tachycardia.
    Nakamura Y; Yamamoto T; Kobayashi S; Tamitani M; Hamada Y; Fukui G; Xu X; Nishimura S; Kato T; Uchinoumi H; Oda T; Okuda S; Yano M
    JCI Insight; 2019 Jun; 4(11):. PubMed ID: 31167968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The arrhythmogenic N53I variant subtly changes the structure and dynamics in the calmodulin N-terminal domain, altering its interaction with the cardiac ryanodine receptor.
    Holt C; Hamborg L; Lau K; Brohus M; Sørensen AB; Larsen KT; Sommer C; Van Petegem F; Overgaard MT; Wimmer R
    J Biol Chem; 2020 May; 295(22):7620-7634. PubMed ID: 32317284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models.
    Penttinen K; Swan H; Vanninen S; Paavola J; Lahtinen AM; Kontula K; Aalto-Setälä K
    PLoS One; 2015; 10(5):e0125366. PubMed ID: 25955245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.